Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 2Recruiting 2Completed 2Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 15Neoplasms 2NSCLC 2Breast Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Sexual Dysfunction, Physiological 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Small Cell Lung Cancer With EGFR Mutation 1Non Small Cell Lung Cancer Metastatic 1NSCLC Patients With Brain Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1Meningeal Carcinomatosis 1Lung Cancer Metastatic 1Locally Advanced or Metastatic Non-squamous NSCLC 1Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Eunuchism 1Erectile Dysfunction 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

Drug Therapy 4Pemetrexed 3Carboplatin 3osimertinib 2Radiotherapy 2toripalimab 1tislelizumab 1sugemalimab 1spartalizumab 1sintilimab 1pembrolizumab 1cemiplimab 1aflutinib 1Vinorelbine 1Radiosurgery 1Platinum 1Paclitaxel 1Gemcitabine 1Docetaxel 1Cisplatin 1Chemotherapy, Adjuvant 1Anterior Temporal Lobectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NSCLC × osimertinib × Clear all
NCT06362980 2024-07-10

EGFR

National Cancer Center, China

Phase 1 Recruiting
20 enrolled
Thoracic

NSCLC

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

TYK Medicines, Inc

Phase 3 Recruiting
680 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡